Kornimate/medical-research-clean huggingface dataset:
sleep and exercise in rheumatoid arthritis

Conditions: Rheumatoid Arthritis; Inflammatory Arthritis

Summary: regular physical activity is important for people with rheumatoid arthritis (ra). sleep requirements for adults should be on a 'sleep needs spectrum' of between 7 to 9 hours per day. poor sleep is a common complaint among people with ra, which may have an effect on their activity levels and well-being. there is evidence that physical activity and exercise can improve sleep quality and disturbances in other chronic disease populations therefore, examining how same affects sleep in ra is important.

sleep is an important aspect in maintaining the body's circadian rhythm. in general getting fewer than 5 hours sleep per day has been associated with cardiovascular problems, diabetes and obesity and can also be linked to depression and anxiety. poor sleep is a common complaint among people with rheumatoid arthritis (ra) with disturbed sleep and fatigue known to affect up to 70% in this population. poor sleep quality may contribute to the feelings of pain, fatigue and poor psychological well-being which in turn may further deteriorate functional ability and reduced activity. it is known that exercise improves a person's psychological state which can also be an additional factor in improving or indeed disrupting quality of sleep. exercise has been identified as an important part of the nonpharmacological management of poor sleep and in improving sleep quality however, people with ra were previously cautioned about undertaking exercise. therefore, changes in sleep quality during exercise intervention should be evaluated so that society can understand more the potential for long-term changes in overall health status, in people who have ra. indeed the intensity level of the activity in people with ra may be of additional importance.

Eligibility criteria:
inclusion criteria: * participants will be eligible to participate if they are aged 18-70; have a diagnosis of ra (defined by the american college of rheumatology 1987 criteria); have poor sleep (pittsburgh sleep quality index global score \>5); have a low disease score on 28 joints (das28) \<3.2; health assessment questionnaire result of \<2.4 and are able to provided informed consent, understand and speak english. all the above will be determined should the person be interested in participating and before any fitness testing will be place. exclusion criteria: * participants will be excluded from the study if they have severe physical disability (haq score \> 2.5); are pregnant; participate in regular physical activity in their leisure time (self-reported aerobic exercise \> 5 times per week); have cardiac symptoms corresponding to new york heart association (nyha) functional classification \> 2;

Keywords: exercise sleep
compare the efficacy and tolerability of the combination of aripiprazole and selective serotonin reuptake inhibitors (ssris) used in major depression

Conditions: Major Depressive Disorder

Summary: fda has accepted atypical antipsychotics of olanzapine and aripiprazole as the adjuvant medications for refractory major depression. but there is still no trial about atypical antipsychotics combined with antidepressant of ssri used in fresh major depressive patients. this project aims to compare the efficacy and tolerability of sertraline with or without low-dosed aripiprazole added in fresh major depression.

this double-blind, placebo-control, fixed dose, randomized study will be conducted at a tertiary clinical setting. patients over 18 y/o fulfilled dsm-iv criteria for major depression, having a baseline ham-d score ≧ 14 and a ham-d item 3 score \< 3 will be recruited into the groups. the study group of patients will receive ten weeks of treatment with a combination of fix-dosed sertraline and aripiprazole. the control group will received sertraline only. the score reduction in ham-d17, cgi, sf-36 and brief symptom rating scale (bsrs-50) will be periodically estimated as an efficacy following the use of a ssris or and aripiprazole.

Eligibility criteria:
inclusion criteria: * male or female subjects 18 to 65 years inclusive. * fulfilled dsm-ⅳ criteria for major depressive disorder. * onset ≧2 weeks. * baseline score ≧14 on the ham-d17. * written informed consent prior to entry into the study. exclusion criteria: * ham-d17 item 3 score≧3. * life-time history of bipolar disorders, schizophrenia or schizoaffective disorder. * current history of panic disorder, obsessive-compulsive disorder, alcohol or substance abuse. * mood disorder due to general medical condition. * treatment with antidepressants at entry into the study before 2 weeks. * need for psychoactive medications other than the study drugs, except for one benzodiazepine or hypnotic given at a stable dose. * known intolerance or inefficacy to either drug. * previous lack of response to two or more antidepressants at adequate dosage. * subjects who have acute or unstable medical illness or organic failure. * pregnancy and breast-feeding.

Keywords: efficacy tolerability combination of aripiprazole and ssri(sertraline)
a phase ii clinical trial of reduced port totally laparoscopic distal gastrectomy with d2 lymph node dissection

Conditions: Gastric Cancer

Summary: the purpose of this study is to determine if reduced port totally laparoscopic distal gastrectomy with complete d2 lymph node dissection for gastric cancer is safe and oncological feasible. 67 patients with gastric cancer with preoperative staging from t1 to t3 will undergo reduced port totally laparoscopic distal gastrectomy. the primary end point of this study is to measure compliance rate with pathology report and compare with previous compliance rate data.


Eligibility criteria:
inclusion criteria: * histologically confirmed adenocarcinoma of the stomach * eastern cooperative oncology group eastern cooperative oncology group performance status 0-1, * signed informed consent * location of the primary tumor in the antrum, angle and lower body * no evidence of distant metastasis or invasion to adjacent organs or serosal infiltration exclusion criteria: * metastatic disease * previous history of malignancy in any organ * any co-morbidity obviating major surgery

Keywords: gastric cancer laparoscope
low voltage electrical stimulation for depression in parkinson's patients

Conditions: Parkinson Disease; Depressive Symptoms

Summary: the goal of this clinical trial is to determine the relative efficacy of fmri model guided transcranial direct current stimulation (mgtdcs) in improving the depressive symptoms of patients with parkinson's disease (pd). the main questions it aims to answer are: 1) can the use of mgtdcs significantly improve the self-reported level of depression and apathy in patients with pd from pre-intervention to post-intervention compared to a sham control? 2) can the use of mgtdcs significantly normalize the cortical eeg alpha asymmetry so commonly seen in depressed patients compared to sham mgtdcs? 3) can the use of mgtdcs significantly improve scores on neuropsychological tests of working memory?

this study seeks to expand the growing body of literature on the use of a particular type of low voltage electrical stimulation known as transcranial direct current stimulation (tdcs) to reduce the symptoms of parkinson's disease (pd). one common disorder that can result from, and/or be exacerbated by pd is major depressive disorder. in particular, apathy has been noted as a common and detrimental component for those with pd. while many studies have been performed on pd patients using tdcs, the consensus in the literature is that results are widely variable. participants will: * complete self-report measures and neuropsychological tests * undergo eeg recording pre and post intervention * participate in 15, 46 minute sessions (2 13 minute stimulation sessions with 20 minutes of rest between) of mgtdcs over the course of 4-5 weeks researchers will compare active mgtdcs to sham mgtdcs to see if active mgtdcs is more effective. a non parkinson's group of depressed controls who are age-matched to the pd patients will serve to determine if treatment effects are specific to pd or generalize to depression more generally.

Eligibility criteria:
inclusion criteria: * 19 to 65 years in age. * parkinson's group must have a physician dx of parkinson's disease * must meet exhibit elevated levels of depression on the beck depression inventory (scores of 20 or above). * must be willing and able to travel of the psychology department for eeg and tdcs sessions. * participants who have undergone surgery for deep brain stimulation implantation may be enrolled if advised to and monitored by their physician. * read and understand spoken english. exclusion criteria: * no history of or being treated for epilepsy or other seizure disorders. * no history of penetrating head wounds or tbi greater than mild tbi. * no history of atypical parkinson's

Keywords: direct transcranial current stimulation
studying gene expression in tissue samples from patients with acute myeloid leukemia

Conditions: Leukemia

Summary: rationale: studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer. purpose: this research study is looking at gene expression in tissue samples from patients with acute myeloid leukemia.

objectives: * screen acute myeloid leukemia (aml) samples to correlate high relative expression levels of plagl2 and putative plagl2 target genes (implicated in microarray study) with potential pathogenic relevance with respect to aml development. outline: cryopreserved mrna from diagnostic samples is analyzed for gene expression by reverse transcriptase-pcr.

Eligibility criteria:
disease characteristics: * diagnosis of acute myeloid leukemia, including inv(16)(p13;q22) abnormalities * no t(15;17)(q22;q12) or t(8;21)(q22;q22) abnormalities patient characteristics: * not specified prior concurrent therapy: * not specified

Keywords: adult acute myeloid leukemia with inv(16)(p13;q22) adult acute myeloid leukemia with 11q23 (mll) abnormalities adult acute myeloid leukemia with del(5q) adult acute myeloid leukemia with t(16;16)(p13;q22) adult acute myeloid leukemia in remission recurrent adult acute myeloid leukemia untreated adult acute myeloid leukemia childhood acute myeloid leukemia in remission recurrent childhood acute myeloid leukemia untreated childhood acute myeloid leukemia and other myeloid malignancies
comparison of total knee arthroplasties with oxidized zirconium and cobalt chromium femoral components

Conditions: Osteoarthritis

Summary: the purpose of this study is to determine if there are any clinical or radiographic differences in cemented total knee arthroplasty with an oxidized zirconium and a cobalt-chromium femoral knee component.

although it has been claimed that total knee arthroplasties with an oxidized zirconium femoral knee component had beneficial wear properties in vitro, there are conflicting clinical results. the purpose of the present study was to compare the clinical, subjective, and radiographic results as well as the weight, size and shape of polyethylene wear particles in the patients with an oxidized zirconium and a cobalt-chromium femoral knee component.

Eligibility criteria:
inclusion criteria: * end-stage osteoarthritis of the knee joint requiring total knee arthroplasty with bilateral disease exclusion criteria: * inflammatory disease * patient with other lower extremity disease which may affect functional outcome * neurologic disease effecting patients lower extremity * revision surgery * patient not medically cleared for bilateral surgery

Keywords: total knee arthroplasty oxidized zirconium genesis ii femoral component cobalt chrome
the effect of schroth exercises on pulmonary function in adolescent idiopathic scoliosis

Conditions: Adolescent Idiopathic Scoliosis; Pulmonary Function

Summary: background: in the present study, we aimed to evaluate the effect of regular schroth exercises on pulmonary functions in adolescent idiopathic scoliosis (ais) patients who use rigid braces and perform schroth exercises regularly. objective: the main purpose of this study, is to investigate the effects of schroth exercises on pulmonary functions in adolescents who use rigid braces and perform schroth exercises regularly. methods: twenty-four patients with ais were included in the study. the patients who wore rigid braces and performed the sse therapy constituted the "brace\&exercise" (n=12), and the patients who wore full-time rigid braces but did not perform exercise constituted the "brace group" (n=12) of the study. the effects of schroth exercises on pulmonary functions were measured at the beginning of treatment and the 8th week of the treatment. keywords: adolescent, idiopathic scoliosis, conservative treatment, brace, respiratory function, schroth exercises.


Eligibility criteria:
inclusion criteria: * 10-16 years, * 25-45 cobb degree, * brace and exercise treatment prescribed by the physician * participation in the study was approved by the family/caregiver exclusion criteria: * chronic respiratory diseases, * professional athletes, * did not perform the exercises regularly * did not compliance the brace
a phase iiib study comparing two boosted protease inhibitor-based haart regimens in hiv-infected patients experiencing their first virologic failure while receiving an nnrti-containing haart regimen

Conditions: HIV Infections

Summary: the purpose of this study is to compare the anti-hiv efficacy, safety and effect of serum lipids of two boosted protease inhibitor-based haart regimens (arv/rtv v. lpv/rtv) in hiv-1 infected subjects who have experienced their first virologic failure while receiving a nnrti-containing haart regimen.


Eligibility criteria:
inclusion criteria: * patients ≥ 18 years of age infected with hiv * plasma hiv rna ≥ 1000 copies/ml and cd4 cell count ≥ 50 cells/mm3 * currently receiving a nnrti-containing haart regimen or not currently receiving a nnrti-containing haart regimen and have not been treated with an alternative regimen since the documented virologic failure (with genotype performed within 2 weeks of the discontinuation of the failing regimen and the genotype report is available) * the failing nnrti-containing regimen must be the patient's first virologic failure on treatment and contain a nnrti and at least 2 nrtis. the regimen must have been administered for at least 24 weeks and the patient must have documented virologic response to the regimen (hiv rna \< 400 c/ml) exclusion criteria: * pregnancy or breastfeeding * reported virologic failure to two or more antiretroviral regimens * active aids-defined opportunistic infection or disease * proven or suspected acute hepatitis within 30 days prior to study entry

Keywords: hiv/aids treatment experienced
study using esomeprazole as a diagnostic test for gerd in patients with nccp

Conditions: Gastroesophageal Reflux Disease

Summary: gastroesophageal reflux disease (gerd), with its cardinal symptom, heartburn, is the most common disorder of the esophagus in the west. comparatively, gerd is less common in singapore but its frequency in the population is increasing. although the vast majority of patients with gerd have heartburn and acid regurgitation, gerd can present in atypical ways, including as a non-cardiac chest pain (nccp). we have previously shown that gerd is a common cause of nccp in singapore. up to 40% of our patients with nccp had endoscopic esophagitis, abnormal 24-hour ph monitoring results, and/or a positive acid perfusion test. these tests, although diagnostic, are costly, labour intensive, and not always readily available in the primary care setting. a trial of high-dose proton pump inhibitor (e.g. omeprazole 60 mg daily) has been proposed as a simple, safe, non-invasive and reliable means to diagnose gerd in western patients with nccp. we have not used the test routinely in our practice. this study will evaluate the use of a short course of esomeprazole, the s-isomer of omeprazole, as a diagnostic test for detecting gerd in patients with nccp. the hypothesis is that in nccp patients with gerd, esomeprazole will resolve their symptoms. consecutive patients diagnosed with nccp at the national university hospital, singapore, will be invited to participate in the study. eligible patients will be randomly assigned to receive either esomeprazole (40 mg o d) for 14 days, or comparable dose of placebo at a similar schedule for 14 days, in a double-blinded fashion. at the start of the study, all subjects will complete a baseline symptom assessment. symptoms will be scored on a graded scale based on severity. during the study weeks, each patient will record his/her own daily symptoms. the patient will be assessed again after the 14-day treatment. the primary outcome measure will be the change in symptom score after initiation of treatment.


Eligibility criteria:
inclusion criteria: * patients with recurrent chest pain of more than three months duration with either (1) normal or non-obstructive coronary arteries (\<50% luminal diameter narrowing), (2) normal dobutamine stress echocardiography or (3) a negative exercise electrocardiogram and a cardiologist's evaluation that symptoms are not cardiac in origin. exclusion criteria: * patients will be excluded if they are \ 70 years old, are pregnant, have a medical contraindication for esomeprazole therapy, have already been empirically treated with an antireflux regimen, report a history of peptic ulcer disease or gastrointestinal surgery, or are unwilling or unable to provide informed consent. in addition, patients who are unable to fully complete all stages of the study will be excluded.

Keywords: noncardiac chest pain gastroesophageal reflux disease diagnostic test proton pump inhibitor esomeprazole
substudy of protocol tb-018 (nct01755598): collection and storage of biological samples for evaluation of correlates of tb (c-041-972)

Conditions: Tuberculosis

Summary: this is an independent optional sub-study parallel to tb-018 (nct01755598) in which biological samples will be collected for future investigations on biological correlates, markers or prognostic factors for tb disease. subjects who consent to enroll in tb-018, "a phase iib, double-blind, randomised, placebo-controlled study to evaluate the efficacy, safety and immunogenicity of gsk biologicals' candidate tuberculosis (tb) vaccine gsk 692342 (m72/as01e) against tb disease, in healthy adults aged 18-50 years, living in a tb endemic region", (see nct 01755598) will be asked to participate in this sub-study. subjects enrolled in tb-018 who also consent to c-041-972 will be followed according to the tb-018 protocol but will have additional blood samples collected for the sub-study.

additional information in the protocol

Eligibility criteria:
inclusion criteria: to be eligible for this sub-study, subjects must be enrolled in tb-018 and provide separate written informed consent for c-041-972. see nct 01755598 for inclusion criteria into tb-018. exclusion criteria: to be eligible for this sub-study, subjects must be enrolled in tb-018 and provide separate written informed consent for c-041-972. see nct 01755598 for exclusion criteria into tb-018.

Keywords: correlates of risk tb tuberculosis sub-study tb-018
dexmedetomidine versus fentanyl on postoperative analgesic profile in laparoscopic sleeve gastrectomy

Conditions: Pain, Postoperative

Summary: dexmedetomidine (dex) activates the α2 adrenergic receptor that is present within the locus coeruleus, leading to anxiolysis, hypnosis, analgesia, and sedation. we conducted our research to compare the effects of fentanyl and dex on the postoperative analgesic profile and complications in morbidly obese patients after sleeve gastrectomy.

the participants were assigned to two groups of equal size (32 patients in each group) by the use of computer-generated numbers and sealed opaque envelopes. the participants allocated to the dex group, also known as group d, received an intravenous loading dose of dex (1 μg/kg) over 15 minutes prior to the anesthetic induction. following the intubation procedure, a maintenance infusion of dex was delivered at a rate of 0.6 μg/kg/h. the infusion was discontinued upon trocars removal. the patients assigned to the fentanyl group (referred to as group f) were administered fentanyl (1 μg/kg) that was given intravenously slowly over 60 seconds before induction of anesthesia as a loading dose. following intubation, a continuous infusion of fentanyl was administered at a rate of 1μg/kg/hr. the infusion was discontinued upon the removal of the trocars.

Eligibility criteria:
inclusion criteria: * body mass index (bmi) of 35 kg/m2 or more. * american society of anesthesiology (asa) physical status of ii-iii. * all participants would have a laparoscopic sleeve gastrectomy (lsg). exclusion criteria: * allergy to α2 -adrenergic agonist. * kidney, liver, neuromuscular disorders, and cardiac disease. * or patients on opioid medications.

Keywords: dexmedetomidine, fentanyl, analgesia,sleeve gastrectomy
early versus late concurrent chemoradiation for limited stage small-cell lung cancer

Conditions: Small Cell Lung Cancer

Summary: the purpose of the study is to evaluate the efficacy and toxicity of different timing of concurrent chemoradiation in the treatment of limited disease status small-cell lung cancer.


Eligibility criteria:
inclusion criteria: * histologically confirmed small-cell lung cancer * limited disease status * with evaluable disease * 18 years or older * ecog performance status 0,1,2 * expected survival time should be 12 weeks or longer * adequate organ function as evidenced by the following; absolute neutrophil count \> 1.5 x 109/l; platelets \> 100 x 109/l; total bilirubin ≤1.5 unl; ast and/or alt \< 5 unl; creatinine clearance ≥ 50ml/min * written informed consent form exclusion criteria: 1. uncontrolled systemic illness such as dm, chf, unstable angina, hypertension or arrhythmia 2. patients with active infection requiring antibiotics 3. pregnant or nursing women ( women of reproductive potential have to agree to use an effective contraceptive method) 4. prior history of malignancy within 5 years from study entry except for a adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer, well-treated thyroid cancer 5. previous history of chemotherapy or radiotherapy

Keywords: limited disease